Date: 2013-10-07
Type of information: Fundraising
Company: Pharmalink (Sweden)
Investors: Industrifonden (Sweden), Investinor (Norway), private investors
Amount: SEK 96 million (€ 11 million)
Funding type: share issue
Planned used: Pharmalink is a specialty pharma company that improves and refines existing drugs. Its current projects are Nefecon® as a treatment for nephritis and Busulipo® as a treatment for bone marrow transplantation. The company has raised capital in order to implement clinical studies of Nefecon® and prepare Busulipo® for clinical trials. Pharmalink is also seeking commercial partners outside the Nordic region and plans to establish a Nordic sales organization.
Others: * On October 7, 2013, the Swedish specialty pharma company Pharmalink has raised SEK 96 million (€ 11 million) in a share issue led by Industrifonden and Investinor Industrifonden and Investinor of Norway are investing a combined SEK 79 million in the specialty pharma company Pharmalink. Industrifonden has been a part-owner of Pharmalink since 2004. The Norwegian investment organization Investinor is joining as a new part-owner. The investment is part of a recently announced collaboration between Industrifonden and Investinor aimed at providing life science companies with access to international capital. Private investors are also participating in the share issue, which totals SEK 96 million. The money will be used for the further development of Pharmalink’s product portfolio.
Pharmalink is a specialty pharma company that improves and refines existing drugs. Its current projects are Nefecon® as a treatment for nephritis and Busulipo® as a treatment for bone marrow transplantation.
Therapeutic area: Kidney diseases - Renal diseases - Transplantation
